In a significant move for public health, the Tamil Nadu government has decided to ban the sale and distribution of Coldrif cough syrup throughout the state. This decision follows alarming reports linking the medication to the tragic deaths of several children in Madhya Pradesh and Rajasthan. The ban reflects rising worries about the safety of pharmaceuticals and the effectiveness of regulatory oversight. The Tamil Nadu Department of Drugs Control Administration (DDCA) made the announcement after early investigations indicated that Coldrif syrup contained diethylene glycol (DEG), a hazardous industrial chemical. DEG is not approved for use in medicines and is notorious for causing severe kidney damage, with links to fatal poisoning cases around the globe. The issue first emerged in late September when hospitals in Madhya Pradesh reported a series of unexplained deaths among children being treated for coughs and colds. Soon after, a similar situation was observed in Rajasthan. Initial lab tests revealed harmful chemicals in Coldrif syrup, leading to urgent health warnings and further investigations. According to officials from the DDCA, the ban on Coldrif syrup is a crucial step to prevent any more harm. All existing stock of the product has been confiscated, and distribution has been stopped. Drug inspectors have been instructed to ensure that pharmacies, wholesalers, and distributors in Tamil Nadu comply with this ban. “Public safety is our highest priority,” a spokesperson for the DDCA stated. “The discovery of diethylene glycol in a medication intended for children is extremely concerning, and we are committed to taking all necessary actions to prevent such incidents from happening again.” At the same time, the Drug Controller General of India (DCGI) has ordered an inspection of the manufacturing facility in Kancheepuram, Tamil Nadu, where Coldrif syrup is made. This inspection will evaluate quality control practices and investigate how the contamination occurred.
